108 related articles for article (PubMed ID: 16098293)
1. Monitoring cardiac function in patients receiving doxorubicin.
Lu P
Semin Nucl Med; 2005 Jul; 35(3):197-201. PubMed ID: 16098293
[TBL] [Abstract][Full Text] [Related]
2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
3. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
Alexander J; Dainiak N; Berger HJ; Goldman L; Johnstone D; Reduto L; Duffy T; Schwartz P; Gottschalk A; Zaret BL
N Engl J Med; 1979 Feb; 300(6):278-83. PubMed ID: 759880
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.
Hayakawa H; Komada Y; Hirayama M; Hori H; Ito M; Sakurai M
Med Pediatr Oncol; 2001 Jul; 37(1):4-9. PubMed ID: 11466716
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.
Mitani I; Jain D; Joska TM; Burtness B; Zaret BL
J Nucl Cardiol; 2003; 10(2):132-9. PubMed ID: 12673177
[TBL] [Abstract][Full Text] [Related]
6. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.
Choi BW; Berger HJ; Schwartz PE; Alexander J; Wackers FJ; Gottschalk A; Zaret BL
Am Heart J; 1983 Oct; 106(4 Pt 1):638-43. PubMed ID: 6613807
[TBL] [Abstract][Full Text] [Related]
7. Late cardiotoxicity after treatment for a malignant bone tumor.
Postma A; Bink-Boelkens MT; Beaufort-Krol GC; Kengen RA; Elzenga NJ; Schasfoort-van Leeuwen MJ; Schraffordt koops H; Kamps WA
Med Pediatr Oncol; 1996 Apr; 26(4):230-7. PubMed ID: 8600333
[TBL] [Abstract][Full Text] [Related]
8. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
9. Selective right ventricular dysfunction following doxorubicin therapy.
Sperber AD; Cantor AA; Biran H; Keynan A
Isr J Med Sci; 1987 Aug; 23(8):896-9. PubMed ID: 3679793
[TBL] [Abstract][Full Text] [Related]
10. Radionuclide ejection fraction in doxorubicin cardiotoxicity.
Morgan GW; McIlveen BM; Freedman A; Murray IP
Cancer Treat Rep; 1981; 65(7-8):629-38. PubMed ID: 7248982
[TBL] [Abstract][Full Text] [Related]
11. Assessment of myocardial viability.
Travin MI; Bergmann SR
Semin Nucl Med; 2005 Jan; 35(1):2-16. PubMed ID: 15645391
[TBL] [Abstract][Full Text] [Related]
12. Antimyosin cardiac imaging: will it play a role in the detection of doxorubicin cardiotoxicity?
Jain D; Zaret BL
J Nucl Med; 1990 Dec; 31(12):1970-4. PubMed ID: 2266395
[No Abstract] [Full Text] [Related]
13. Adriamycin (doxorubicin) cardiotoxicity: a review.
Chlebowski RT
West J Med; 1979 Nov; 131(5):364-8. PubMed ID: 394479
[TBL] [Abstract][Full Text] [Related]
14. Late echocardiography assessment of systolic and diastolic function of the left ventricle in pediatric cancer survivors after anthracycline therapy.
Santin JC; Deheinzelin D; Junior SP; Lopes LF; de Camargo B
J Pediatr Hematol Oncol; 2007 Nov; 29(11):761-5. PubMed ID: 17984694
[TBL] [Abstract][Full Text] [Related]
15. [Damage of left ventricular function after treatment with doxorubicin in patients with malignant lymphomas].
Elbl L; Chaloupka V; Vásová I; Nehyba S; Vorlícek J; Navrátil M; Kiss I; Cíhalová M
Vnitr Lek; 2000 Nov; 46(11):768-75. PubMed ID: 15637892
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.
Nousiainen T; Vanninen E; Jantunen E; Remes J; Ritanen E; Vuolteenaho O; Hartikainen J
Clin Sci (Lond); 2001 Dec; 101(6):601-7. PubMed ID: 11724646
[TBL] [Abstract][Full Text] [Related]
17. Newest echocardiographic techniques for the detection of cardiotoxicity and heart failure during chemotherapy.
Sawaya H; Plana JC; Scherrer-Crosbie M
Heart Fail Clin; 2011 Jul; 7(3):313-21. PubMed ID: 21749883
[TBL] [Abstract][Full Text] [Related]
18. [Early detection of cardiotoxicity of anthracyclines. Value of isotopic method].
Massing JL; Caillot D; Mouhat T; Schlesser P; Solary E
Arch Mal Coeur Vaiss; 1996 Jan; 89(1):57-62. PubMed ID: 8678739
[TBL] [Abstract][Full Text] [Related]
19. Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity.
Steinberg JS; Wasserman AG
Clin Ther; 1985; 7(6):660-7. PubMed ID: 3907840
[TBL] [Abstract][Full Text] [Related]
20. Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.
Vorobiof DA; Iturralde M; Falkson G
Cancer Chemother Pharmacol; 1985; 15(3):253-7. PubMed ID: 3863718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
